NCT00407277View on ClinicalTrials.gov

Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

August 31, 2008

Conditions
SmokingNicotine DependenceSchizophreniaSchizophreniform DisordersSchizoaffective DisorderPsychosis
Interventions
DRUG

Nicotine patch

21 mg of nicotine via a dermal patch

OTHER

placebo

placebo via a dermal patch

BEHAVIORAL

smoking cessation group therapy

"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
collaborator

Canadian Psychiatric Research Foundation

OTHER

lead

Centre for Addiction and Mental Health

OTHER

NCT00407277 - Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia | Biotech Hunter | Biotech Hunter